Week in Review: MicroConstants Pays $16 Million for Novel China Antibody

MicroConstants China in-licensed global rights to novel discovered-in-China AA98 antibodies for cancer and other diseases from Beijing's Institute of Biophysics in a $16 million deal; China Traditional Chinese Medicine Co. will pay as much as $1.3 billion for an 82% stake in fellow TCM maker Jiangyin Tianjiang Pharma; 3SBio of Shenyang acquired Sirton Pharmaceuticals SpA, a Northern Italy CMO/CRO with a focus on injected drugs; Fosun Pharma signed a framework agreement to build a hospital with First Hospital of Qiqihar City; Waters Corporation, a US lab equipment maker, and the Chinese Pharmacopeia Commission officially opened the Joint Open Laboratory in Beijing to set TCM standards; Novotech, an Australian CRO, announced an enlarged, permanent office in Hong Kong to run clinical trials; and Menarini Asia-Pacific received China approval to market Kerasal Nail™, an OTC fungal nail product made by Moberg Pharma AB of Sweden. More details.... Stock Symbols: (HK: 570) (SHA: 600196; HK: 02196) (NYSE: WAT) (OMX: MOB) Share this with colleagues: // //